GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · BSE Equity Only

BSE Exchange Filings, Explained Simply

AI-powered plain-English analysis of every important BSE announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Strictly sourced from BSE exchange announcements (equity segment only). We show only material, important filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India exchange announcements. More categories will be added over time.
Ipca Laboratories Ltd
Outcome of Board Meeting
M&A ◆ Monitor Closely LOW RISK
📅 Filed on BSE: 26 Jun 2026, 01:09 PM IST  ·  BSE ID: 31da2546-2b9d-45f4-808a-f30fcd35c36a
View Original BSE Filing (PDF)
💡
In Simple Terms
Ipca Laboratories' board approved merging with Krebs Biochemicals to gain specialized manufacturing and secure supply chain.
🤖 AI Summary
  • Ipca Laboratories Board approved the Scheme of Amalgamation with Krebs Biochemicals & Industries Ltd.
  • Appointed Date for the merger is April 1, 2026, subject to regulatory approvals.
  • Krebs Biochemicals & Industries Ltd. had a total income of Rs. 26 Crores for FY26.
  • Ipca Laboratories Ltd. reported a standalone audited total income of Rs. 7431 Crores for FY26.
  • Share exchange ratio is 7 equity shares of Ipca for every 200 equity shares of Krebs Biochemicals.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Ipca Laboratories Standalone Audited Total Income (FY26)
Rs. 7431 Crores
Krebs Biochemicals Audited Total Income (FY26)
Rs. 26 Crores
Share Exchange Ratio
7 equity shares of Ipca for every 200 equity shares of Krebs Biochemicals
🏢 How This Affects the Company
📈
Business Impact
The merger will consolidate the business of Krebs Biochemicals with Ipca Laboratories, potentially increasing the combined entity's business volume and enabling new fermentation-based API development. It will secure uninterrupted supply of a critical API and drug intermediates.
💰
Financial Impact
The amalgamation is expected to result in operational synergies and cost optimization due to consolidated business operations. Krebs Biochemicals is continuously incurring losses, which Ipca Laboratories' financial strength aims to mitigate post-merger.
⚙️
Operational Impact
The integration will provide Ipca Laboratories with manufacturing facilities and capabilities for fermentation-based Active Pharmaceutical Ingredients (APIs) it currently lacks. It also centralizes administrative responsibilities, records, and compliance requirements.
⚠️
Risk Impact
The merger addresses the risk of supply chain disruptions for a key API and drug intermediates used in Ipca Laboratories' largest selling formulation. It also reduces the risk associated with Krebs Biochemicals' continuous losses by integrating it into a financially stronger entity.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from existing shareholders of Ipca Laboratories Ltd. at this stage.
👤
Who Is Affected
Shareholders of Krebs Biochemicals & Industries Ltd. will receive 7 equity shares of Ipca Laboratories for every 200 shares held in Krebs Biochemicals. Existing Ipca Laboratories shareholders will experience the impact of the merger post-approvals.
🔍
Management Signal
The decision signals management's intent to enhance operational efficiency, strengthen supply chain security for critical products, and expand manufacturing capabilities in fermentation-based APIs.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
SEBI and NCLT approvals for the Scheme of Amalgamation.
Announcement of the Effective Date for the merger.
Subsequent financial results for consolidated performance post-merger.
LOW RISK The merger aims to reduce existing supply chain and operational risks for Ipca Laboratories.
💡 Investor Takeaway
Ipca Laboratories' Board approved merger with Krebs Biochemicals & Industries Ltd., effective from April 1, 2026. This secures API supply, brings fermentation-based API capabilities, and consolidates business, with Krebs Biochemicals reporting Rs. 26 Crores income for FY26.
⚖️ Strengths & Concerns

✅ Positives

  • Secures uninterrupted supply of a critical fermentation-based API and drug intermediates for Ipca Laboratories' key products.
  • Provides Ipca Laboratories with new manufacturing capabilities for fermentation-based APIs and facilities for R&D in this area.

⚠️ Concerns

  • Krebs Biochemicals & Industries Ltd. is continuously incurring losses, which Ipca Laboratories will absorb post-merger.
  • The transaction is a related party transaction, although stated to be done at arm's length basis.
📅 Company Track Record
Previous filings indicated that Ipca Laboratories Board approved merger with Krebs Biochemicals (Rs. 26 Cr income FY26) for synergies. This filing confirms the details and terms of that approved merger, including the share exchange ratio.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the purpose of the merger between Ipca Laboratories and Krebs Biochemicals?
The merger aims to achieve operational synergies, cost optimization, secure uninterrupted supply of critical Active Pharmaceutical Ingredients (APIs), and expand Ipca Laboratories' manufacturing capabilities for fermentation-based APIs.
What was the total income of Krebs Biochemicals & Industries Ltd. for the financial year ended March 31, 2026?
The Audited Total Income of Krebs Biochemicals & Industries Ltd. for the financial year ended March 31, 2026, was Rs. 26 Crores.
What is the share exchange ratio for the amalgamation?
As consideration, Ipca Laboratories Ltd. will issue 7 fully paid-up equity shares of Re. 1/- each for every 200 fully paid-up equity shares of Rs. 10/- each held in Krebs Biochemicals & Industries Ltd.
Is the merger between Ipca Laboratories and Krebs Biochemicals a related party transaction?
Yes, the transaction is a related party transaction and is being done on an arm’s length basis, as per the filing.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.